

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018

November 16, 2017 - InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2018 Annual General Meeting, which will be held on Thursday May 24, 2018. The responsibility of the Nomination Committee is to present to the 2018 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditor.

The Nomination Committee for the 2018 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of:

- David Sonnek, appointed by SEB Venture Capital/SEB Stiftelsen
- Jonas Jendi, appointed by Industrifonden
- Pål Jensen, appointed by NeoMed/N5
- Anni Fuhr, appointed by Rune Petterson
- Wenche Rolfsen, Chairman of the Board (convener)

The Nomination Committee together represents approximately 60 percent of all voting rights in the company as of September 30, 2017.

Shareholders wishing to submit comments or proposals to the Nomination Committee can send them via email to info@indexpharma.com.

In addition, the Board of InDex Pharmaceuticals Holding AB (publ) has decided on the dates for the financial reporting 2018.

Calendar for the financial reporting 2018

Year-end report 2017 – February 26, 2018

Interim report QI 2018 – May 17, 2018

Annual General Meeting 2018 – May 24, 2018

Interim report QII 2018 – August 28, 2018

Interim report QIII 2018 – November 19, 2018

Note that the date of publication of the company's year-end report for 2017 has been postponed compared to what was previously communicated.

For more information:

Peter Zerhouni, CEO

Phone: +46 8 508 847 35

E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com